BrightPath Biotherapeutics Co.Ltd. (JP:4594)
:4594
Top Page
BrightPath Biotherapeutics Co.Ltd.
(4594)
Select Model
Select Model
Rating:50Neutral
Price Target:
¥64.00
▲(33.33% Upside)
Action:ReiteratedDate:03/27/26
The score is held down primarily by weak financial performance (ongoing losses and negative cash flow), partially offset by an improving/strong price trend with positive momentum indicators. Valuation is constrained by negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Revenue Growth
Revenue expanded sharply (over 1,000% YoY), showing the company has achieved a step-change in top-line traction. Durable high revenue growth can finance continued R&D and commercialization, de-risking long-term execution if margins and cash conversion improve.
Negative Factors
Persistent Net Losses
The company has sustained negative operating and net results over multiple periods, indicating structural unprofitability. Ongoing losses erode reserves and hinder internal funding of growth; without a clear path to consistent operating profitability, long-term viability depends on external capital or radical cost and revenue changes.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Revenue expanded sharply (over 1,000% YoY), showing the company has achieved a step-change in top-line traction. Durable high revenue growth can finance continued R&D and commercialization, de-risking long-term execution if margins and cash conversion improve.
Read all positive factors
BrightPath Biotherapeutics Co.Ltd. (4594) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥9.03B
Dividend YieldN/A
Average Volume (3M)2.78M
Price to Earnings (P/E)―
Beta (1Y)1.09
Revenue Growth1221.43%
EPS Growth30.54%
CountryJP
Employees42
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.54
Shares Outstanding138,891,300
10 Day Avg. Volume4,086,650
30 Day Avg. Volume2,782,203
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)3.88
Price to Sales (P/S)3165.29
P/FCF Ratio-2.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BrightPath Biotherapeutics Co.Ltd. Business Overview & Revenue Model
Company Description
BrightPath Biotherapeutics Co., Ltd. develops cancer immunotherapy drugs. The company is developing GRN-1201 that is in Phase II clinical study for the treatment of non-small cell lung cancer, as well as in Phase I clinical study to treat melanoma...
How the Company Makes Money
null...
BrightPath Biotherapeutics Co.Ltd. Financial Statement Overview
Summary
Income Statement
20
Very Negative
Balance Sheet
40
Negative
Cash Flow
25
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 118.00K | 1.13M | 72.00K | 5.28M | 15.41M | 2.50M |
| Gross Profit | -5.00M | 1.10M | -341.00K | -13.33M | -23.03M | -65.33M |
| EBITDA | -1.19B | -1.16B | -1.15B | -1.45B | -1.44B | -1.67B |
| Net Income | -1.21B | -1.15B | -1.17B | -1.49B | -1.48B | -1.72B |
Balance Sheet | ||||||
| Total Assets | 1.43B | 1.12B | 1.23B | 1.70B | 2.77B | 3.75B |
| Cash, Cash Equivalents and Short-Term Investments | 1.30B | 810.47M | 1.06B | 1.53B | 2.31B | 3.27B |
| Total Debt | 500.00M | 25.00M | 112.50M | 0.00 | 87.50M | 0.00 |
| Total Liabilities | 655.82M | 195.62M | 251.27M | 133.91M | 239.73M | 211.79M |
| Stockholders Equity | 772.75M | 924.99M | 978.99M | 1.57B | 2.53B | 3.54B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -1.25B | -1.16B | -1.21B | -1.53B | -1.81B |
| Operating Cash Flow | 0.00 | -1.25B | -1.16B | -1.20B | -1.51B | -1.77B |
| Investing Cash Flow | 0.00 | -1.37M | -7.65M | -1.76M | -17.57M | -36.21M |
| Financing Cash Flow | 0.00 | 1.00B | 690.96M | 432.10M | 569.23M | 2.05B |
BrightPath Biotherapeutics Co.Ltd. Technical Analysis
Negative
48.00
Price Trends
68.60
Negative
61.70
Positive
64.94
Positive
Market Momentum
-0.87
Positive
46.45
Neutral
22.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4594, the sentiment is Negative. The current price of 48 is below the 20-day moving average (MA) of 71.50, below the 50-day MA of 68.60, and below the 200-day MA of 64.94, indicating a neutral trend. The MACD of -0.87 indicates Positive momentum. The RSI at 46.45 is Neutral, neither overbought nor oversold. The STOCH value of 22.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4594.
BrightPath Biotherapeutics Co.Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | ¥7.92B | 59.41 | ― | 1.24% | -14.78% | -95.53% | |
56 Neutral | ¥7.75B | 33.49 | ― | ― | 2.99% | -52.75% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥9.03B | -2.75 | ― | ― | 1221.43% | 30.54% | |
50 Neutral | ¥49.01B | -13.30 | ― | ― | -82.33% | 47.73% | |
49 Neutral | ¥11.31B | -8.14 | ― | ― | -42.49% | -2.37% | |
45 Neutral | ¥19.24B | -11.30 | ― | ― | ― | 11.34% |
* Healthcare Sector Average
JP:4594
BrightPath Biotherapeutics Co.Ltd.
65.00
26.00
66.67%
JP:4593
Healios KK
363.00
106.00
41.25%
JP:4599
StemRIM Inc.
307.00
22.00
7.72%
JP:4880
CellSource Co., Ltd.
399.00
-213.85
-34.89%
JP:7096
StemCell Institute
756.00
-554.00
-42.29%
JP:7776
CellSeed Inc.
291.00
-262.00
-47.38%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.